Published in Shock on August 01, 2004
The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem (2009) 0.77
Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia. PLoS One (2015) 0.75
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
A good death. Intensive Care Med (2006) 2.52
A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2012) 2.39
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
Accuracy and feasibility of point-of-care and continuous blood glucose analysis in critically ill ICU patients. Crit Care (2006) 2.01
[Primary surgery by a gynecological oncologist improves the prognosis in patients with ovarian carcinoma]. Ned Tijdschr Geneeskd (2009) 1.97
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol (2006) 1.79
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Mean glucose level is not an independent risk factor for mortality in mixed ICU patients. Intensive Care Med (2006) 1.76
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature. Crit Care (2006) 1.70
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Quality of interhospital transport of critically ill patients: a prospective audit. Crit Care (2005) 1.57
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients: Response to Plank et al. Diabetes Care (2006) 1.55
Pleiotropic effects of angiopoietin-2 deficiency do not protect mice against endotoxin-induced acute kidney injury. Nephrol Dial Transplant (2012) 1.55
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med (2002) 1.49
Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med (2014) 1.48
Quality of interhospital transport of the critically ill: impact of a Mobile Intensive Care Unit with a specialized retrieval team. Crit Care (2011) 1.46
Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target? Crit Care (2009) 1.45
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care (2009) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
The effect of chronotype on sleepiness, fatigue, and psychomotor vigilance of ICU nurses during the night shift. Intensive Care Med (2015) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med (2007) 1.32
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Inter-hospital transport of critically ill patients; expect surprises. Crit Care (2012) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine (2011) 1.29
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
Prone positioning of patients with acute respiratory failure. N Engl J Med (2002) 1.18
Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. Intensive Care Med (2010) 1.18
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol (2010) 1.14
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Effect of vemurafenib on a V600R melanoma brain metastasis. Eur J Cancer (2013) 1.13
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab (2009) 1.11
PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol (2013) 1.10
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10
PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med (2012) 1.10
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer (2006) 1.08
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
Augmented renal clearance in critically ill: advantage or threat. Crit Care Med (2014) 1.08
Considerations on absence of 68Ga-DOTA-F(ab')2-trastuzumab tracer uptake in HER2-overexpressing tumor lesions. Nucl Med Commun (2014) 1.07